Stage-stratified benefits of AI-radiomics PET in early Alzheimer’s disease: a systematic review and meta-analysis - Takeaways - MDSpire

Stage-stratified benefits of AI-radiomics PET in early Alzheimer’s disease: a systematic review and meta-analysis

  • By

  • Jinglu Duan

  • Meixuan Yang

  • Yong Wang

  • May 15, 2026

  • 0 min

Share

  • 1

    AI-enhanced PET radiomics shows promise in diagnosing Alzheimer's disease, outperforming traditional methods in early detection.

  • 2

    The systematic review included nine studies with 5,765 participants, highlighting significant heterogeneity in diagnostic performance.

  • 3

    Proteinopathy PET demonstrated superior sensitivity and specificity compared to 18F-FDG PET in distinguishing Alzheimer's from mild cognitive impairment.

  • 4

    The advantages of AI-radiomics were minimal when comparing Alzheimer's disease to healthy controls, indicating limited additional value.

  • 5

    The study emphasizes the need for multi-site validation and standardized reporting to enhance the reliability of AI-enhanced PET diagnostics.

Original Source(s)

Stage-stratified benefits of AI-radiomics PET in early Alzheimer’s disease: a systematic review and meta-analysis

  • by Jinglu Duan, Meixuan Yang, Yong Wang

  • May 15, 2026

Related Content

Observing and treating pain in people living with dementia in long-term care facilities

Enrique Diaz, M.D., Joins Baptist Health Miami Neuroscience Institute as a Psychiatrist

Board-certified psychiatrist Enrique Diaz, M.D., has joined Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain & Spine Care.

  • by

  • April 30, 2026

  • 2 min
Amyloid-targeting treatment in Alzheimer's disease and concomitant antiplatelets: a clinical gray zone?